Compare
China Pharma Holdings, Inc. vs ProPhase Labs, Inc. vs Whitehawk Therapeutics, Inc. vs Aclaris Therapeutics, Inc.
| Latest fiscal year | China Pharma Holdings, Inc. CPHI | ProPhase Labs, Inc. PRPH | Whitehawk Therapeutics, Inc. WHWK | Aclaris Therapeutics, Inc. ACRS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $4.14M | $4.34M | $7.14M | $7.83M |
| Revenue growth (YoY) | -8.5% | -35.8% | -72.5% | -58.2% |
| Gross margin | -3.2% | 31.9% | 89.4% (computed) | 73.3% (computed) |
| Operating margin | -78.2% | -415.4% | n/m | -975.9% |
| Net margin | -76.9% | -339.3% | -288.3% | -829.6% |
| Net income | -$3.19M | -$14.74M | -$20.60M | -$64.92M |
| EPS (Diluted) | -$0.74 | -$1.74 | -$0.33 | -$0.53 |
| Operating cash flow | $148.3K | -$8.34M | -$97.43M | -$47.11M |
| Free cash flow | $88.9K | -$8.34M | -$97.98M | -$47.22M |
| Cash & equivalents | $345.1K | $90.0K | $37.57M | $19.96M |
| Total assets | $31.00M | $59.87M | $150.83M | $160.46M |
| Total liabilities | $8.26M | $56.36M | $14.52M | $57.38M |
| Shareholders' equity | $22.74M | $3.51M | $136.31M | $103.08M |
| Return on year-end equity | -14.0% | -420.3% | -15.1% | -63.0% |
| Shares outstanding | 15.52M | 8.97M | 47.15M | 120.50M |
Revenue, most recent five fiscal years
| Fiscal year | China Pharma Holdings, Inc. | ProPhase Labs, Inc. | Whitehawk Therapeutics, Inc. | Aclaris Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $4.14M Ended 2025-12-31 | $4.34M Ended 2025-12-31 | $7.14M Ended 2025-12-31 | $7.83M Ended 2025-12-31 |
| 1 year earlier | $4.53M Ended 2024-12-31 | $6.77M Ended 2024-12-31 | $25.98M Ended 2024-12-31 | $18.72M Ended 2024-12-31 |
| 2 years earlier | $7.01M Ended 2023-12-31 | $34.98M Ended 2023-12-31 | $24.35M Ended 2023-12-31 | $31.25M Ended 2023-12-31 |
| 3 years earlier | $8.10M Ended 2022-12-31 | $122.65M Ended 2022-12-31 | $15.22M Ended 2022-12-31 | $29.75M Ended 2022-12-31 |
| 4 years earlier | $9.64M Ended 2021-12-31 | $79.04M Ended 2021-12-31 | $14.00M Ended 2021-12-31 | $6.76M Ended 2021-12-31 |